<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03988049</url>
  </required_header>
  <id_info>
    <org_study_id>IRB_00095294</org_study_id>
    <nct_id>NCT03988049</nct_id>
  </id_info>
  <brief_title>Comparison of 1,550 and 755 Laser in a Split-face Trial</brief_title>
  <official_title>Comparison of a 1,550 Nanometer Erbium: Glass Fractional Laser and 755-nanometer Alexandrite Picosecond Pulse Duration Laser With Diffractive Lens Array in the Treatment of Acne Scars: a Randomized, Split-face Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Smart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical Trial comparing the 1,550-nanometer fractionated photothermolysis system laser to&#xD;
      the 755 nanometer picosecond laser using a split-face (Right-Left) comparison. Patients will&#xD;
      receive laser treatments at week 0, week 4, and week 8. Photographs will be taken prior to&#xD;
      laser treatment at each visit, and at the week 24 follow-up visit. Photographs will be&#xD;
      reviewed by blinded assessors to rate each side of the face and change from baseline photos.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Clinical Trial comparing the 1,550-nanometer fractionated photothermolysis system&#xD;
      laser to the 755 nanometer picosecond laser using a split-face (Right-Left) comparison. Both&#xD;
      of these lasers are currently FDA approved for acne scarring.&#xD;
&#xD;
      Approximately 18 subjects, men and women with Fitzpatrick skin types I through V and facial&#xD;
      acne scarring of grades III-IV (moderate to severe) will be enrolled. Both sides of the&#xD;
      participants' face should have similar amount and severity of acne scarring. Participants&#xD;
      will be over 18 years old. Patients have to be otherwise healthy without a history of skin&#xD;
      cancer, keloidal scarring, localized or active infection, immunodeficiency disorders, and&#xD;
      light sensitivity.&#xD;
&#xD;
      Patients have to be overall healthy without a history of skin cancer, keloidal scarring,&#xD;
      localized or active infection, immunodeficiency disorders, and light sensitivity. Per PI&#xD;
      discretion, any serious medical condition that may interfere with the study. In addition,&#xD;
      patients who have been taking isotretinoin for a period of 6 months before treatment will be&#xD;
      excluded.&#xD;
&#xD;
      Patients will have photographs taken at every visit prior to the laser treatments at week 0,&#xD;
      week 4, and week 8. Photographs will also be taken at the week 24 follow-up visit. Photos&#xD;
      will then be assessed by qualified blinded reviewers for comparison.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 8, 2017</start_date>
  <completion_date type="Actual">October 30, 2019</completion_date>
  <primary_completion_date type="Actual">August 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All subjects will receive half of their faces treated with each laser. Subjects will be randomized to determine which side of the face is treated with each laser.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Blinded Assessors will be reviewing and scoring the photos after the study is completed.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Half Faces to Achieve at Least 25% Improvement in Acne Scarring at Week 24 by Blinded Photo Reviewer</measure>
    <time_frame>Photos will be taken at week 0, week 4, week 8, and week 24.</time_frame>
    <description>Change in Baseline acne scarring compared to week 24 measured by photographic review. Measured by blinded reviewer assessments of photographs.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Acne Scars - Mixed Atrophic and Hypertrophic</condition>
  <arm_group>
    <arm_group_label>1,550 laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm is the side of the face treated with the 1550-nanometer Fracionated Photothermolysis laser.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>755 laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm is the side of the face treated with the 755-nanometer alexandrite picosecond laser.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>1,550 fracionated photothermolysis laser</intervention_name>
    <description>All subjects will have one side of their face treated with one laser, and the other side with the other laser.</description>
    <arm_group_label>1,550 laser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>755 picosecond laser</intervention_name>
    <description>All subjects will have one side of their face treated with one laser, and the other side with the other laser.</description>
    <arm_group_label>755 laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women with Fitzpatrick skin types I through V and facial acne scarring of&#xD;
             grades III-IV (moderate to severe) will be enrolled. Both sides of the participants'&#xD;
             face should have similar amount and severity of acne scarring. Participants will be&#xD;
             over 18 years old. Patients have to be otherwise healthy without a history of skin&#xD;
             cancer, keloidal scarring, localized or active infection, immunodeficiency disorders,&#xD;
             and light sensitivity.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients have to be overall healthy without a history of skin cancer, keloidal&#xD;
             scarring, localized or active infection, immunodeficiency disorders, and light&#xD;
             sensitivity. Per PI discretion, any serious medical condition that may interfere with&#xD;
             the study. In addition, patients who have been taking isotretinoin for a period of 6&#xD;
             months before treatment will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R Smart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah MidValley Dermatology</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2019</study_first_posted>
  <results_first_submitted>February 17, 2021</results_first_submitted>
  <results_first_submitted_qc>June 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 29, 2021</results_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>David Smart</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT03988049/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1,550 Laser</title>
          <description>All subjects on this arm will be treated on this split-faced. This arm is looking at the side of the face treated with the 1,550-nanometer Fracionated Photothermolysis laser.&#xD;
1,550 fracionated photothermolysis laser vs. 755 picosecond laser: All subjects will have one side of their face treated with one laser, and the other side with the other laser.</description>
        </group>
        <group group_id="P2">
          <title>755 Laser</title>
          <description>All subjects on this arm will be treated on this split-faced. This arm is the side of their face will be treated with the 755-nanometer alexandrite picosecond laser.&#xD;
1,550 fracionated photothermolysis laser vs. 755 picosecond laser: All subjects will have one side of their face treated with one laser, and the other side with the other laser.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>There were 22 participants total, but each participate received each treatment on half of their face. Therefore, there are 22 participants in each arm, with at total of 22 participants. But there are 44 half faces analyzed in the trial.</population>
      <group_list>
        <group group_id="B1">
          <title>1,550 Laser</title>
          <description>All subjects on this arm will be treated on this split-faced. This arm consists of the half-faces treated with the 1,550-nanometer Fracionated Photothermolysis laser.&#xD;
1,550 fracionated photothermolysis laser vs. 755 picosecond laser: All subjects will have one side of their face treated with one laser, and the other side with the other laser.</description>
        </group>
        <group group_id="B2">
          <title>755 Laser</title>
          <description>All subjects on this arm will be treated on this split-faced. This arm consists of the half-faces treated with the 755-nanometer alexandrite picosecond laser.&#xD;
1,550 fracionated photothermolysis laser vs. 755 picosecond laser: All subjects will have one side of their face treated with one laser, and the other side with the other laser.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>half faces</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Number of units analyzed was 2 per participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>the number of units analyzed was 2 per participant.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="14.28"/>
                    <measurement group_id="B2" value="33" spread="14.28"/>
                    <measurement group_id="B3" value="33" spread="14.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>the number of units analyzed was 2 per participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>Each participant received both lasers (one on each side of the face). So there are 22 participants total, however, there are 22 halves of faces on each treatment arm.</description>
          <population>the number of units analyzed was 2 per participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>the number of units analyzed was 2 per participant.</population>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Half Faces to Achieve at Least 25% Improvement in Acne Scarring at Week 24 by Blinded Photo Reviewer</title>
        <description>Change in Baseline acne scarring compared to week 24 measured by photographic review. Measured by blinded reviewer assessments of photographs.</description>
        <time_frame>Photos will be taken at week 0, week 4, week 8, and week 24.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1,550 Laser</title>
            <description>All subjects on this arm will be treated on this split-faced. This arm is looking at the side of the face treated with the 1,550-nanometer Fracionated Photothermolysis laser.&#xD;
1,550 fracionated photothermolysis laser vs. 755 picosecond laser: All subjects will have one side of their face treated with one laser, and the other side with the other laser.</description>
          </group>
          <group group_id="O2">
            <title>755 Laser</title>
            <description>All subjects on this arm will be treated on this split-faced. This arm is the side of their face will be treated with the 755-nanometer alexandrite picosecond laser.&#xD;
1,550 fracionated photothermolysis laser vs. 755 picosecond laser: All subjects will have one side of their face treated with one laser, and the other side with the other laser.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Half Faces to Achieve at Least 25% Improvement in Acne Scarring at Week 24 by Blinded Photo Reviewer</title>
          <description>Change in Baseline acne scarring compared to week 24 measured by photographic review. Measured by blinded reviewer assessments of photographs.</description>
          <units>half faces</units>
          <param>Count of Units</param>
          <units_analyzed>half faces</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>half faces</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (anticipated and unanticipated) related to study treatments/procedures (based on the judgment of an investigator) were collected from the time of signed consent through week 24.</time_frame>
      <desc>The adverse events collected for this study differ from the clinicaltrials.gov definition in that the adverse events collected were only considered related to the participant's participation in the research.</desc>
      <group_list>
        <group group_id="E1">
          <title>1,550 Laser</title>
          <description>This arm is the side of the face treated with the 1550-nanometer Fracionated Photothermolysis laser.&#xD;
1,550 fracionated photothermolysis laser: All subjects will have one side of their face treated with one laser, and the other side with the other laser.</description>
        </group>
        <group group_id="E2">
          <title>755 Laser</title>
          <description>This arm is the side of the face treated with the 755-nanometer alexandrite picosecond laser.&#xD;
755 picosecond laser: All subjects will have one side of their face treated with one laser, and the other side with the other laser.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Transient Erythema</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="22"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Transient Crusting or Blistering</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="22"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Smart, Assistant Professor, Dermatology</name_or_title>
      <organization>University of Utah Dermatology</organization>
      <phone>8015816465</phone>
      <email>david.smart@hsc.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

